NCT01786967View on ClinicalTrials.gov

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Urge Urinary Incontinence
Interventions
DRUG

Fesoterodine Fumarate

FDA approved anticholinergic medication used for treatment of urge urinary incontinence

Trial Locations (1)

27599

UNC-Chapel Hill, Dept of Ob/Gyn, Chapel Hill

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT01786967 - Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) | Biotech Hunter | Biotech Hunter